INTENSITY THERAPEUTICS, INC. (INTS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45828J2024
INTENSITY THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -11.97 m USD |
| EBIT | -11.79 m USD |
| Net income | -11.61 m USD |
| Diluted EPS – continuing operations | -8.56 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About INTENSITY THERAPEUTICS, INC.
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
More stocks
- CJ Seafood Corp. Pfd. Series 1 (011155.KS)
- InMed Pharmaceuticals Inc. (INM)
- Rise Gold Corp. (RYES)
- HeartSciences Inc. (HSCS)
- JEWETT CAMERON TRADING CO LTD (JCTC)
- AtlasClear Holdings, Inc. (ATCH)
- Sintx Technologies, Inc. (SINT)
- Sky Quarry Inc. (SKYQ)
- Thunder Power Holdings, Inc. (AIEV)
- ACCENDRA HEALTH INC/VA/ (ACH)
- BullFrog AI Holdings, Inc. (BFRG)
- Greenland Technologies Holding Corp. (GTEC)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.